What value do norepinephrine/dopamine dual reuptake inhibitors have to the current treatment of adult attention deficit hyperactivity disorder (ADHD) treatment armamentarium?

References

• Franke B, Michelini G, Asherson P, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2018;28(10):1059–1088.
   PubMed Web of Science ®Google Scholar
• Skirrow C, Asherson P. Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder. J Affect Disord. 2013;147(1–3):80–86.
   PubMed Web of Science ®Google Scholar
• Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. 2009;57(7–8):579–589.
   PubMed Web of Science ®Google Scholar
• Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209–225.
   PubMed Web of Science ®Google Scholar
• Demontis D, Walters RK, Martin J, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51(1):63–75.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. Clinical Guideline [CG87] [Internet]. 2018. www.nice.org.uk/guidance/ng87
   Google Scholar
• Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2002;27(5):699–711.
   PubMed Web of Science ®Google Scholar
• Singh A, Balasundaram MK, Singh A. Viloxazine for attention-deficit hyperactivity disorder: a systematic review and meta-analysis of randomized clinical trials. J Cent Nerv Syst Dis. 2022;14:11795735221092522.
   Web of Science ®Google Scholar
• Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9): 727–738.
   PubMed Web of Science ®Google Scholar
• Verbeeck W, Bekkering GE, Van den Noortgate W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017;10(10):CD009504.
   PubMedGoogle Scholar
• Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–270.
   PubMed Web of Science ®Google Scholar
• Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239–247.
   PubMed Web of Science ®Google Scholar
• Coghill D, Banaschewski T, Zuddas A, et al. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry. 2013;13(1):237.
   PubMedGoogle Scholar
• Cândido RCF, Menezes de padua CA, Golder S, et al. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2021;1(1):CD013011.
   PubMedGoogle Scholar
• Robinson DM, Keating GM. Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder. Drugs. 2006;66(5):661–670.
   PubMed Web of Science ®Google Scholar
• Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018;8(8):CD007813.
   PubMedGoogle Scholar
• Underhill SM, Hullihen PD, Chen J, et al. Amphetamines signal through intracellular TAAR1 receptors coupled to Gα(13) and Gα(S) in discrete subcellular domains. Mol Psychiatry. 2021;26(4):1208–1223.
   PubMed Web of Science ®Google Scholar
• Dela Peña I, Gevorkiana R, Shi W-X. Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms. Eur J Pharmacol. 2015;764:562–570.
   PubMed Web of Science ®Google Scholar
• Brams M, Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73(7):977–983.
   PubMed Web of Science ®Google Scholar
• Adler LA, Dirks B, Deas PF, et al. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(7):694–702.
   PubMed Web of Science ®Google Scholar
• Brown TE, Chen J, Robertson B. Improved executive function in adults diagnosed with attention-deficit/ hyperactivity disorder as measured by the brown attention-deficit disorder scale following treatment with SHP465 mixed amphetamine salts extended-release: post hoc analyses from 2 Ra. J Atten Disord. 2022;26(2):256–266.
   PubMed Web of Science ®Google Scholar
• Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006;6(9):1249–1265.
   PubMed Web of Science ®Google Scholar
• Lenzi F, Cortese S, Harris J, et al. Pharmacotherapy of emotional dysregulation in adults with ADHD: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;84:359–367.
   PubMed Web of Science ®Google Scholar
• Perugi G, Vannucchi G, Bedani F, et al. Use of stimulants in bipolar disorder. Curr Psychiatry Rep. 2017 19;19(1). http://www.springerlink.com/content/1523-3812/
   PubMed Web of Science ®Google Scholar
• Viktorin A, Rydén E, Thase ME, et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry. 2017;174(4):341–348. http://www.ncbi.nlm.nih.gov/pubmed/27690517
   PubMed Web of Science ®Google Scholar
• Yanofski J. The dopamine dilemma: using stimulants and antipsychotics concurrently. Psychiatry (Edgmont). 2010;7(6):18–23.
   PubMedGoogle Scholar
• Crunelle CL, van den Brink W, Moggi F, et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur Addict Res. 2018;24(1): 43–51.
   PubMed Web of Science ®Google Scholar